retatrutide clinical development ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial When will Retatrutide be available
Description
Diabetes Care 28:1936-1940, 2005 [ Links ] 138
Stolwyk, K
GIP Receptor Distribution: **Adipose tissue: Adipocyte metabolism, nutrient partitioning Brain: Modulates energy balance Bone: May positively influence bone metabolism Clinically, this translates into greater weight loss than GLP-1 aloneoften approaching or exceeding 20% of body weight in trials
Sustained Support & Lifestyle Integration Our commitment extends beyond just medication
Who Can Use Wegovy
Tirzepatide is administered once weekly via subcutaneous injection, and whilst there is no specific time of day recommended in the prescribing information, maintaining a consistent weekly schedule is important
